Pneumococcal IgA1 protease subverts specific protection by human IgA1

Mucosal Immunology

Volumn 7, Issue 2, 2014, Pages 249-256

  Janoff, E N ^a   Rubins, J B ^b   Fasching, C ^c   Charboneau, D ^b   Rahkola, J T ^a   Plaut, A G ^d   Weiser, J N ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A1; IMMUNOGLOBULIN A1 MONOCLONAL ANTIBODY; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN A2 MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROTEINASE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL IMMUNITY; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUTROPHIL; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTECTION; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; SERINE ENDOPEPTIDASES; STREPTOCOCCUS PNEUMONIAE;

EID: 84895132729     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.41     Document Type: Article

References (53)

1. Dagan, R., Engelhard, D. & Piccard, E. Epidemiology of invasive childhood pneumococcal infections in Israel: The Israeli Pediatric Bacteremia and Meningitis Group. JAMA 268, 3328-3332 (1992).
2. Bruyn, G.A.W., Van Der Meer, J.W.M., Hermans, J. & Knoppert, W. Pneumococcal bacteremia in adults over a 10-year period at University Hospital, Leiden. Rev. Infect. Dis. 10, 446-450 (1988).
3. Jette', L.P. & Lamothe, F. Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: Serotype distribution, antimicrobial susceptibility, and clinical characteristics. J. Clin. Microbiol. 27, 1-5 (1989).
4. Kuikka, A., Syrjanen, J., Renkonen, O.V. & Valtonen, V.V. Pneumococcal bacteraemia during a recent decade. J. Infect. 24, 157-168 (1992).
5. Thigpen, M.C. et al. Bacterial meningitis in the United States, 1998-2007. N. Engl. J. Med. 364, 2016-2025 (2011).
6. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 46, 1-24 (1997).
7. O'Brien, K.L. et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet 374, 893-902 (2009).
8. Brandtzaeg, P. Regionalized immune function of tonsils and adenoids. Immunol. Today 20, 383-384 (1999).
9. Kirkeby, L., Rasmussen, T.T., Reinholdt, J. & Kilian, M. Immunoglobulins in nasal secretions of healthy humans: Structural integrity of secretory immunoglobulin A1 (IgA1) and occurrence of neutralizing antibodies to IgA1 proteases of nasal bacteria. Clin. Diagn. Lab. Immunol. 7, 31-39 (2000).
10. Male, C.J. Immunoglobulin A1 protease production by Haemophilus influenzae and Streptococcus pneumoniae. Infect. Immun. 26, 254-261 (1979).
11. Kilian, M., Mestecky, J. & Schrohenloher, R.E. Pathogenic species of the genus Haemophilus and Streptococcus pneumoniae produce immunoglobulin A1 protease. Infect. Immun. 26, 143-149 (1979).
12. Kilian, M., Mestecky, J., Kulhavy, R., Tomana, M. & Butler, W.T. IgA1 proteases from Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, and Streptococcus sanguis: Comparative immunochemical studies. J. Immunol. 124, 2596-2600 (1980).
13. Mulks, M.H. & Plaut, A.G. IgA protease production as a characteristic distinguishing pathogenic from harmless neisseriaceae. N. Engl. J. Med. 299, 973-976 (1978).
14. Plaut, A.G. The IgA1 proteases of pathogenic bacteria. Annu. Rev. Microbiol. 37, 603-622 (1983).
15. Weiser, J.N. et al. Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proc. Natl. Acad. Sci. USA 100, 4215-4220 (2003).
16. Kilian, M., Reinholdt, J., Lomholt, H., Poulsen, K. & Frandsen, E.V. Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: Critical evaluation of experimental evidence. APMIS 104, 321-338 (1996).
17. Kilian, M., Mestecky, J. & Russell, M.W. Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol. Rev. 52, 296-303 (1988).
18. Janoff, E.N. et al. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J. Clin. Invest. 104, 1139-1147 (1999).
19. Finn, A. et al. Induction of functional secretory IgA responses in breast milk by pneumococcal capsular polysaccharides. J. Infect. Dis. 186, 1422-1429 (2002).
20. Fasching, C.E. et al. Impact of the molecular form of IgA on its functional activity in defense against Streptococcus pneumoniae. Infect. Immun. 75, 1801-1810 (2007).
21. Steinitz, M., Tamir, S., Ferne, M. & Goldfarb, A. A protective human monoclonal IgA antibody produced in vitro: Anti-pneumococcal antibody engendered by Epstein-Barr virus-immortalized cell line. Eur. J. Immunol. 16, 187-193 (1986).
22. Baxendale, H.E. et al. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur. J. Immunol. 30, 1214-1223 (2000).
23. Zhong, Z., Burns, T., Chang, Q., Carroll, M. & Pirofski, L. Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect. Immun. 67, 4119-4127 (1999).
24. Bender, M.H. & Weiser, J.N. The atypical amino-terminal LPNTGcontaining domain of the pneumococcal human IgA1-specific protease is required for proper enzyme localization and function. Mol. Microbiol. 61, 526-543 (2006).
25. Reed, L.J. & Muench, H. A simple method of estimating fifty percent endpoints. Am J. Hyg. 27, 493-497 (1938).
26. Lomholt, H. Evidence of recombination and an antigenically diverse immunoglobulin A1 protease among strains of Streptococcus pneumoniae. Infect. Immun. 63, 4238-4243 (1995).
27. Plaut, A.G., Gilbert, J.V., Artenstein, M.S. & Capra, J.D. Neisseria gonorrhoeae and Neisseria meningitidis: Extracellular enzyme cleaves human immunoglobulin A. Science 190, 1103-1105 (1975).
28. Johannsen, D.B., Johnston, D.M., Koymen, H.O., Cohen,M.S. & Cannon, J.G. A Neisseria gonorrhoeae immunoglobulin A1 protease mutant is infectious in the human challenge model of urethral infection. Infect. Immun. 67, 3009-3013 (1999).
29. Kilian, M., Thomsen, B., Petersen, T.E. & Bleeg, H.S. Occurrence and nature of bacterial IgA proteases. Ann. NY Acad. Sci. 409, 612-624 (1983).
30. Opstad, N.L. et al. Impact of Streptococcus pneumoniae bacteremia and human immunodeficiency virus type 1 on oral mucosal immunity. J. Infect. Dis 172, 566-570 (1995).
31. Vitovski, S., Dunkin, K.T., Howard, A.J. & Sayers, J.R. Nontypeable Haemophilus influenzae in carriage and disease: A difference in IgA1 protease activity levels. JAMA 287, 1699-1705 (2002).
32. Wani, J.H., Gilbert, J.V., Plaut, A.G. & Weiser, J.N. Identification, cloning, and sequencing of the immunoglobulin A1 protease gene of Streptococcus pneumoniae. Infect. Immun. 64, 3967-3974 (1996).
33. Chiavolini, D., Memmi, G., Maggi, T., Ianelli, F., Pozzi, G. & Oggioni, M.R. The three extra-cellular zinc metalloproteinases of Streptococcus pneumoniae have a different impact on virulence in mice. BMC Microbiol. 3, 14 (2003).
34. Polissi, A. et al. Large-scale identification of virulence genes from Streptococcus pneumoniae. Infect. Immun. 66, 5620-5629 (1998).
35. Oggioni, M.R. et al. Pneumococcal zinc metalloproteinase ZmpC cleaves human matrix metalloproteinase 9 and is a virulence factor in experimental pneumonia. Mol. Microbiol. 49, 795-805 (2003).
36. Shen, L., Lasser, R. & Fanger, M.W. My 43, a monoclonal antibody that reacts with human myeloid cells inhibits monocyte IgA binding and triggers function. J. Immunol. 143, 4117-4122 (1989).
37. Monteiro, R.C., Kubagawa, H. & Cooper, M.D. Cellular distribution, regulation, and biochemical structure of an Fc alpha receptor in humans. J. Exp. Med. 171, 597-613 (1999).
38. Patry, C., Sibille, Y., Lehuen, A. & Monteiro, R.C. Identification of Fca receptor (CD89) isoforms generated by alternative splicing that are differently expressed between blood monocytes and alveolar macrophages. J. Immunol. 156, 4442-4448 (1996).
39. Nikolova, E.B., Tomana, M. & Russell, M.W. The role of the carbohydrate chains in complement (C3) fixation by solid-phase-bound human IgA. Immunology 82, 321-327 (1994).
40. Van Egmond, M. et al. IgA and the IgA Fc receptor. Trends Immunol. 22, 205-211 (2001).
41. Dalia, A.B. & Weiser, J.N. Minimization of bacterial size allows for complement evasion and is overcome by the agglutinating effect of antibody. Cell Host Microbe 10, 486-496 (2011).
42. Thiesen, B., Greenwood, B., Brieske, N. & Achtman, M. Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein. Vaccine 15, 209-219 (1997).
43. Kobayashi, K., Fujiyama, Y., Hagiwara, K. & Kondoh, H. Resistance of normal serum IgA and secretory IgA to bacterial IgA proteases: Evidence for the presence of enzyme-neutralizing antibodies in both serum and secretory IgA, and also in serum IgG. Microbiol. Immunol. 31, 1097-1106 (1987).
44. Plaut, A.G., Qiu, J., Grundy, F. & Wright, A. Growth of Haemophilus influenzae in human milk: Synthesis, distribution, and activity of IgA protease as determined by study of iga+ and mutant iga-cells. J. Infect. Dis. 166, 43-52 (1992).
45. Devenyi, A.G., Plaut, A.G.,Grundy, F.J. &Wright, A. Post-infectious human serum antibodies inhibit IgA1 proteinases by interaction with the cleavage site specificity determinant. Mol. Immunol. 30, 1243-1248 (1993).
46. Romanello, V. et al. Cloning, expression, purification, and characterization of Streptococcus pneumoniae IgA1 protease. Protein Expr. Purif. 45, 142-149 (2006).
47. Reinholdt, J. & Kilian, M. Comparative analysis of immunoglobulin A1 protease activity among bacteria representing different genera, species, and strains. Infect. Immun. 65, 4452-4459 (1997).
48. Musher, D.M. et al. Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: Association with nasopharyngeal colonization. Clin. Infect. Dis. 24, 441-446 (1997).
49. Blake, M.S. & Swanson, J. Studies on gonococcus infection. XVI. Purification of Neisseria gonorrhoeae immunoglobulin A1 protease. Infect. Immun. 22, 350-358 (1978).
50. Carroll, W.L., Thielemans, K., Dilley, J. & Levy, R. Mouse-human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 89, 61-72 (1986).
51. Lefkovits, I. &Waldmann, H. Limiting dilution analysis of the cell of immune system I. The clonal basis of immune response. Immunol. Today 5, 265-268 (1984).
52. Johnson, S., Opstad, N.L., Douglas, J.M. Jr. & Janoff, E.N. Prolonged and preferential production of polymeric immunoglobulin A in response to Streptococcus pneumoniae capsular polysaccharides. Infect. Immun. 64, 4339-4344 (1996).
53. Rubins, J.B. et al. Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J. Clin. Invest. 95, 142-150 (1995).